Drug Profile
Umeclidinium/vilanterol - GlaxoSmithKline/Innoviva
Alternative Names: '444+'719; '719/VI; 573719/642444; 642444/573719; Anoro Ellipta; GSK 573719/GW 642444; GSK-2592356; Laventair; UMEC/VI; Vilanterol/GSK 573719; Vilanterol/umeclidiniumLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Theravance
- Developer GSK
- Class Antiasthmatics; Benzhydryl compounds; Bronchodilators; Chlorobenzenes; Ethanolamines; Ethers; Phenols; Quinuclidines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic obstructive pulmonary disease
Most Recent Events
- 20 Sep 2019 Launched for Chronic obstructive pulmonary disease in Italy (Inhalation) before September 2019
- 20 Sep 2019 Launched for Chronic obstructive pulmonary disease in Mexico (Inhalation) before September 2019
- 20 Sep 2019 Launched for Chronic obstructive pulmonary disease in Sweden (Inhalation) before September 2019